Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease

Lancet

Volumn 348, Issue 9025, 1996, Pages 429-432

  Tang, Ming Xin ^a,c   Jacobs, Diane ^a,b,c   Stern, Yaakov ^a,b,c,d   Marder, Karen ^a,b,c   Schofieid, Peter ^a,c   Garland, Barry ^d,f   Andrews, Howard ^b,g   Mayeux, Richard ^a,b,c,d,e,h  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b Taub Center for Alzheimer's Disease Research   (United States)

^c Departments of Neurology   (United States)

^d Department of Psychiatry ^*  (United States)

^e Division of Epidemiology   (United States)

^f UMIDNJ School of Public Health

^g College of Physicians and Surgeons ^*  (United States)

^h NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL SURVIVAL; CHOLINERGIC NERVE CELL; EDUCATION; ESTROGEN THERAPY; ETHNOLOGY; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MENOPAUSE; NERVE CELL GROWTH; NONBIOLOGICAL MODEL; NORMAL HUMAN; ONSET AGE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK; RISK BENEFIT ANALYSIS;

EID: 0030591669     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)03356-9     Document Type: Article

References (28)

1. Bush TL, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality: preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA 1983; 249: 903-06.
2. Ettinger B, Friedman GD, Bush T, Quesenberry CP. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecoi 1996; 87: 6-12.
3. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia - Alzheimer's type. Psychoneuroendocrinology 1986; 11: 337-45.
4. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994; 51: 896-900.
5. Rocca WA, Amaducci LA, Schoenberg BS. Epidemiology of clinically diagnosed Alzheimer's disease. Ann Neurol 1986; 19: 415-24.
6. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994; 140: 256-61.
7. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994; 140: 262-67.
8. Toran-Allerand CD, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992; 89: 4668-72.
9. Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging 1994; 15 (suppl 2): S195-97.
10. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer's amyloid beta precursor protein. J Biol Chem 1994; 269: 13065-68.
11. Honjo H, Tanaka K, Kashiwagi T, et al. Senile dementia-Alzheimer's type and estrogen. Hormone Metab Res 1995; 27: 204-07.
12. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population: development of a neuropsychological paradigm and quantified correction for educated. Arch Neurol 1992; 49: 453-60.
13. Pittman J, Andrews H, Tatemichi T, et al Diagnosis of dementia in a heterogeneous population: a comparison of paradigm-based diagnosis and physician's diagnosis. Arch Neurol 1992; 49: 461-67.
14. Mayeux R, Ottman R, Tang M-X, et al. Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community-dwelling elderly persons and the first-degree relatives. Ann Neurol 1993; 33: 494-501.
15. American Psychiatric Association Diagnostic and statistical manual of mental disorders, 3rd edn, revised. Washington, DC: American Psychiatric Association, 1987: 205-24.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadland E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44.
17. Hixson J, Vernier D. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhAl. J Lipid Res 1991; 31: 545-48.
18. Maestre G, Ottman R, Stern Y, et al. Apolipoprotein-E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 1995; 37: 254-59.
19. Collet D. Modelling survival data in medical research. London: Chapman and Hall, 1994: 153-54.
20. Herbert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995; 273: 1354-59.
21. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990; 28: 766-74.
22. Miranda RC, Sohrabji F, Toran-Allerand CD. Estrogen target neurons co-localize the mRNAs for the neutrophins and their receptors during development: a basis for the interactions of estrogen and the neurotrophins. Mol Cell Neurosci 1993; 4: 510-25.
23. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology 1995; 136: 2320-24.
24. Singh M, Meyer EM, Huang FS, Millard WJ, Simpkins JW. Ovariectomy reduces ChAT activity and NGF mRNA levels in the frontal cortex and hippocampus of the female Sprague Dawley rat. Abstr Soc Neurosci 1993; 19: 1254.
25. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury and amyloid β-peptide toxicity of hippocampal neurons. J Neurochem 1996; 66: 1836-44.
26. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-72.
27. Roses AD, Strittmatter WJ, Pericak-Vance MA, Corder EH, Saunders AM, Schmechel DE. Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet 1994; 343: 1564-65.
28. Henderson AS, Easteal S, Jorm AF, et al. Apolipoprotein E allele ε4, dementia, and cognitive decline in a population sample. Lancet 1995; 346: 1387-90.